Table 2.

Performance characteristics of reported ELISA systems for the detection of autoantibodies in autoimmune bullous dermatoses.

ELISAa	Disease	Sensitivityb	Specificityb	References
Anti-Dsg1c	Pemphigus foliaceus	96 – 100%	96–100%	(147, 159, 165–169)
Anti-Dsg3c	Pemphigus vulgaris	85–100%	96–100%	(147, 159, 165–173)
Anti-envoplakind	Paraneoplastic pemphigus	63–83%	91–98%	(36–38)
Anti-periplakin	Paraneoplastic pemphigus	74%	96%	(36)
Anti-desmocollin	Paraneoplastic pemphigus	60%	NA	(33)
Anti-BP180e	Bullous pemphigoid	54–95%	90–100%	(50, 51, 53, 106, 143, 144, 160, 164, 165, 169, 173–181)
Anti-BP230f	Bullous pemphigoid	48–82%	65–99%	(50, 51, 53, 54, 106, 144, 165, 175–177, 182)
Anti-laminin 332	Mucous membrane pemphigoid	20–75%	84–96%	(71, 163)
Anti-laminin γ1	Anti-lamininγ1/p200 pemphigoid	69%	99%	(162)
Anti-type VII collageng	Epidermolysis bullosa acquisita	86–100%	98–100%	(114, 149, 161, 183–186)
Anti-deamidated gliadin	Dermatitis herpetiformis, coeliac disease	84–95% (IgA)	86–93% (IgA)	(92, 145)
		80–99% (IgG)	93–94% (IgG)
Anti-tissue transglutaminase	Dermatitis herpetiformis, coeliac disease	78–98%	96–99%	(92, 94, 145, 187–189)

^aParameters for which commercial ELISA systems are not available are indicated in italics.

^bIncluding performance data reported for commercial and in-house assays.

^cCommercial assays employ the ectodomains of Dsg1 and Dsg3 after recombinant expression in baculovirus (MBL) or HEK293 cells (Euroimmun).

^dCommercial assay based on the N-terminal envoplakin 1–481 fragment (Euroimmun).

^eCommercial assays employ a single recombinant NC16A domain (MBL) or a tetramer of four NC16A domains to increase epitope exposure (BP180-NC16A-4X, Euroimmun).

^fCommercial assays employ recombinant protein of both N- and C-terminal parts of BP230 (MBL) or only a fragment of the C-terminal domain (BP230_2326−2649, Euroimmun).

^gCommercial assays employ the NC1 and NC2 domains of type VII collagen (MBL) or only NC1 (Euroimmun).